Insilico Medicine signed a multiyear R&D collaboration with France’s Servier valued at as much as $888 million to apply Insilico’s AI discovery platform to oncology programs, following the company’s recent Hong Kong IPO that raised roughly $292 million. The agreement will fund AI‑driven target selection and candidate generation while Servier will lead clinical validation, regulatory interactions, and commercialization for resulting assets. Insilico framed the deal as validation of its Pharma.AI platform and a pathway to scale AI‑led oncology discovery with an established clinical partner. The transaction underscores continued investor and pharma appetite for AI‑enabled discovery firms after public market entries in Asia.